Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Limited, formerly TRIMURT HI LIMITED, will hold a board meeting on Wednesday, November 11, 2026, to consider and approve unaudited standalone financial results for the quarter and half year ended September 30, 2026, along with a limited review report from the auditors. The company, with Scrip Code 586565 and Scrip Id NOVELIX, has closed the trading window for designated persons and their immediate relatives from October 1, 2026, until 48 hours after the board meeting’s conclusion.

Novelix Pharmaceuticals Limited, formerly TRIMURT HI LIMITED, submitted a certificate to the BSE Limited under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, as confirmed by its Registrar and Share Transfer Agent, M/s. Venture Capital and Corporate Investments Private Limited.

Novelix Pharmaceuticals Limited, formerly Trimurt Hi Limited, announced that its members approved the appointment of Mr. Gnana Prakash Gattu as a Whole Time Director for a period of 5 years, effective August 29, 2026, at the company's 32nd Annual General Meeting held on September 30, 2026. Mr. Gattu, who belongs to the Promoters and Promoter group of the company, is a graduate from IIT-Chennai and has over 25 years of experience in management and information technology and is not debarred from holding the office of Director by any regulatory authority.

Novelix Pharmaceuticals Limited, formerly TRIMURT HI LIMITED, will close its trading window for designated persons and their relatives from Thursday, October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ended September 30, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Novelix Pharmaceuticals Limited, formerly TRIMURT HI LIMITED, announced the appointment of Mr. Gnana Prakash Gattu as a Whole Time Director for a period of five years, effective August 29, 2026, subject to shareholder approval, according to a filing with the BSE Limited. Mr. Gattu, who is part of the company's Promoter and Promoter group, holds a degree from IIT-Chennai and has over 25 years of experience in management and information technology.

Novelix Pharmaceuticals Limited, formerly TRIMURT HI LIMITED, will hold a board meeting on Saturday, August 29, 2026, to discuss the notice of its 32nd Annual General Meeting, approve the Board Report for the financial year ended March 31, 2026, appoint a scrutinizer for the AGM and remote e-voting, and consider the appointment of Mr. Gnana Prakash Gattu (DIN:00517921) as Whole Time Director.

Novelix Pharmaceuticals Limited, formerly TRIMURT HI LIMITED, will hold a board meeting on Thursday, August 13, 2026, to consider and approve the unaudited standalone financial results for the quarter ended June 30, 2026, along with a limited review report from the auditors. The company, with Scrip Code 586565 and Scrip Id NOVELIX, has closed the trading window for designated persons and their immediate relatives from July 1, 2026, until 48 hours after the board meeting’s conclusion, in accordance with SEBI regulations.

Novelix Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 1 July 2026.

Astaxanthin is a potent, naturally occurring carotenoid antioxidant. It is primarily used as a dietary supplement to combat oxidative stress, reduce inflammation, and support healthy skin, eyes, and cardiovascular function The company clarified that GMBU e.V. and its affiliates are not related to the promoter, promoter group, or group companies of Novelix Pharmaceuticals. The transaction does not fall under related-party transactions, and no promoter or promoter group entity has any interest in the agreement. Novelix Pharmaceuticals is engaged in business of trading of pharmaceuticals and related products and is into the business of trading of shares and securities. The companys; consolidated net profit surged 405.56% to Rs 0.91 crore on 20.76% jump in revenue from operations to Rs 25.19 crore in Q4 FY26 over Q4 FY25. The counter rallied 3.28% to end at Rs 54.40 n the BSE.Powered by Capital Market - Live

Net profit of Novelix Pharmaceuticals rose 405.56% to Rs 0.91 crore in the quarter ended March 2026 as against Rs 0.18 crore during the previous quarter ended March 2025. Sales rose 20.76% to Rs 25.19 crore in the quarter ended March 2026 as against Rs 20.86 crore during the previous quarter ended March 2025. For the full year,net profit rose 3100.00% to Rs 2.56 crore in the year ended March 2026 as against Rs 0.08 crore during the previous year ended March 2025. Sales rose 330.70% to Rs 132.31 crore in the year ended March 2026 as against Rs 30.72 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales25.1920.86 21 132.3130.72 331 OPM %5.081.10 -2.630.46 - PBDT1.280.23 457 3.510.16 2094 PBT1.230.21 486 3.410.12 2742 NP0.910.18 406 2.560.08 3100 Powered by Capital Market - Live